Papaverine
- Atc Codes:A03AD01#G04BE02
- CAS Codes:61-25-6#58-74-2
- PHARMGKB ID:61-25-6#58-74-2
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Belgium: Papaverine; Bulgaria: Papaverin, Papaverinum; Czech Republic: Papaverin; France: Papaverine; Germany: Paveron N; Hungary: Neo-Bilagit, Papaverin; Italy: Papave, Papaverina; Netherlands: Papaverine; Poland: Papaverinum; Portugal: Papaverina; Romania: Papaverina; Slovakia: Papaverin; Sweden: Papaverin, Spasmofen.
North America
Canada: Papaverine.
Latin America
Argentina: Papaverina.
Asia
Japan: Papaverine.
Drug combinations
Papaverine and Edetate Calcium Disodium
Papaverine, Atropine, and Metamizole
Papaverine, Codeine, and Morphine
Other Papaverine combinations: Belladonna; Dipyrone; Homatropine
Chemistry
Papaverine Hydrochloride: C~20~H~21~NO~4~ HCl. Mw: 375.85. (1) Isoquinoline, 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-, hydrochloride; (2) 6,7-Dimethoxy-1-veratrylisoquinoline hydrochloride. CAS-61-25-6; CAS-58-74-2 (papaverine).
Pharmacologic Category
Vasodilating Agents, Miscellaneous. (ATC-Code: A03AD01; G04BE02).
Mechanism of action
Smooth muscle spasmolytic producing generalized smooth muscle relaxation, which might occur due to inhibition of cyclic nucleotide phosphodiesterase, increasing cyclic AMP. Papaverine increases cerebral blood flow in normal subjects. Oxygen uptake unaltered.
Therapeutic use
Relief of peripheral and cerebral ischemia associated with arterial spasm and myocardial ischemia complicated by arrhythmias.
Pregnancy and lactiation implications
Use with caution during pregnancy or lactation.
Unlabeled use
Investigational: Various vascular spasms associated with muscle spasms as in myocardial infarction, angina, peripheral and pulmonary embolism, peripheral vascular disease, angiospastic states, and visceral spasm (ureteral, biliary, and GI colic). Testing for impotence.
Contraindications
Hypersensitivity to papaverine or any component of the formulation.
Warnings and precautions
May (in large doses or with rapid infusion) depress AV and intraventricular cardiac conduction leading to serious arrhythmias (e.g. premature beats, paroxysmal tachycardia). May cause hepatic hypersensitivity (eosinophilia with abnormal LFTs). Use with caution in glaucoma. Apnea and arrhythmias may result from intravenous administration.